PHARMACOKINETIC STUDY OF MATRIX MEMBRANE MODERATED TRANSDERMAL SYSTEM OF BOSENTAN MONOHYDRATE
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i9.19282Keywords:
Bosentan monohydrate, In vitro diffusion studies, Pharmacokinetic studiesAbstract
Objective: The objective of the present research work is to carry out the pharmacokinetic studies of optimized matrix membrane moderatedtransdermal patch of bosentan monohydrate.
Materials and Methods: The matrix membrane moderated transdermal system was formulated using HPMC, HPMC K4M and E RLPO. In vitrodiffusion studies were carried out using modified Franz diffusion cell and for the optimized transdermal patch, pharmacokinetic studies were carriedout using New Zealand male rabbits. Plasma samples were quantified using high-performance liquid chromatography.
Results: The in vitro diffusion studies revealed that formulation F3 with HPMC K4M and E RLPO had controlled release up to 28 hrs, and a maximumof 95.02±2.68% drug was released. The release kinetics followed mixed order non-Fickian diffusion. The pharmacokinetic studies of the optimizedpatch revealed controlled release up to 45 hrs where a 2.2-fold increase in area under curve (AUC) and 3.8 times increase in mean residence time(MRT) were observed compared to oral route. The results were appeared to be significant at p≤0.05. The variation in half-life was found to be notstatistically significant when compared between oral and transdermal routes.
Conclusion: The pharmacokinetic results concluded that the matrix membrane moderated transdermal system with extended AUC and MRT canenhance the bioavailability of bosentan monohydrate by minimizing the drug-related side effects in oral route.
Downloads
References
O’Callaghan DS, Savale L, Montani D, Jaïs X, Sitbon O, Simonneau G,et al. Treatment of pulmonary arterial hypertension with targetedtherapies. Nat Rev Cardiol 2011;8(9):526-38.
Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A,et al. Combination of bosentan with epoprostenol in pulmonary arterialhypertension: BREATHE-2. Eur Respir J 2004;24(3):353-9.
Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T,et al. Guidelines on diagnosis and treatment of pulmonary arterialhypertension. The task force on diagnosis and treatment of pulmonaryarterial hypertension of the European society of cardiology. Eur Heart J2004;25(24):2243-78.
Opitz CF, Ewert R, Kirch W, Pittrow D. Inhibition of endothelinreceptors in the treatment of pulmonary arterial hypertension: doesselectivity matter? Eur Heart J 2008;29(16):1936-48.
New Zealand Data Sheet Pms Bosentan; 2012. Available from: http://www.medsafe.govt.nz/profs/datasheet/p/pmsbosentantab.pdf.
Guy RH, Hadgraft J. Selection of drug candidates for transdermal drugdelivery. In: Transdermal Drug Delivery. New York: Marcel Dekker;1989. p. 59-83.
Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal andtransdermal drug delivery systems: current and future prospects. DrugDeliv 2006;13(3):175-87.
Revathi M, Indira MY. Formulation and evaluation of matrix membranemoderated transdermal patches of bosentan monohydrate. Int J Sci EngRes 2015;6(10):746-53.
Seema A, Nida A, Shivsankar B. Transdermal delivery a preclinical andclinical perspective of drugs delivered via patches. Int J Pharm PharmSci 2014;6(5):26-38.
Kevin CG, Anil JS, Pratik HS. Formulation and in-vitro characterizationof monolithic matrix transdermal systems using Hpmc/Eudragit s 100polymer blends. Int J Pharm Pharm Sci 2009;1(1):108-20.
Paranjyothy KL, Thampi PP. Development of transdermal patches ofverapamil hydrochloride using carboxymethyl guar gum as a monolithicpolymeric matrix and their in vitro release studies. Indian J Pharm Sci1997;52:49-54.
Anissimov YG, Roberts MS. Modelling dermal drug distribution after topical application in human. Pharm Res 2011;28(9):2119-29.
Prasad Verma PR, Chandak AR. Development of matrix controlledtransdermal delivery systems of pentazocine: In vitro/in vivoperformance. Acta Pharm 2009;59:171-86.
Ubaidulla U, Reddy MV, Ruckmani K, Ahmad FJ, Khar RK.Transdermal therapeutic system of carvedilol: effect of hydrophilic andhydrophobic matrix on in vitro and in vivo characteristics. AAPS PharmSci Tech 2007;8(1):2.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
